Zhitong Finance App News, Baiyunshan (00874) issued an announcement. Recently, Guangzhou Baiyunshan Chen Liji Pharmaceutical Co., Ltd. (hereinafter referred to as “Chen Liji Pharmaceutical Factory”), a subsidiary of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”), received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration on the treatment of the new functions of Soojianjian Waist Pills.
Chen Liji Pharmaceutical Co., Ltd. submitted a clinical trial application to the State Drug Administration on June 25, 2026 for treatment of increasing the function of Shu Jianjian waist pills, which was accepted on July 23, 2026. The main functions of loin relief pills are to nourish the liver and kidney, strengthen muscles and bones, expel wind and moisture, and relieve pain. For lower back and knee pain. This product is a traditional Chinese medicine compound preparation that has already been marketed. This is an application for additional use for lumbar disc herniation caused by hepatic and renal insufficiency and rheumatic stasis.
As of the date of this announcement, Chen Liji Pharmaceutical has invested approximately RMB 2,054 million (RMB, same below) (unaudited) in exploratory clinical research on the efficacy, mechanism, and efficacy of Shu Jianjian Knee Pill to treat lumbar disc herniation.
Shu Jianjian's lower back pills are an exclusive variety of Chen Liji Pharmaceutical. Similar products sold in China mainly include Danlu Tongdu tablets, lower back pain relief capsules, etc. According to the Mi Intranet database, domestic sales of these similar products in 2025 were 512 million yuan, 285 million yuan, and 192 million yuan, respectively. In 2025, Chen Liji Pharmaceutical's sales revenue of Shu Jianjian Knee Pills was 120 million yuan.